? Metabolomics Core Based on the success of the Cancer Metabolism Developing Shared Resource and growing scientific needs of ACC members, the ACC established the Metabolomics Core as a full-fledged Shared Resource, with an expanded array of services. Dr. Daniel Kelly, Ware Professor of Diabetes and Metabolic Diseases, has assumed leadership of this Shared Resource. Dr. Kelly is a well-recognized expert in mitochondrial metabolism and leader in the study of the metabolic origins of diseases in his over 25-year career. This new Shared Resource is staffed by Technical Director Dr. Christopher Petucci, along with a fully trained analytical chemist. Dr. Petucci has over 20 years of experience in mass spectrometry, including extensive expertise in measuring metabolites in cells, biological fluids, and tissues from animals and humans. The Metabolomics Core provides critically needed state-of-the-art targeted and untargeted metabolomics and lipidomics services to ACC researchers, which are extremely cost-effective compared to the out-sourcing used in the past. The Metabolomics Core: 1) provides well-validated, quantitative, targeted liquid chromatography-mass spectrometry (LC/MS) metabolomics of 127 metabolites from samples including cells, plasma, and tissues; 2) provides untargeted metabolomics and lipidomics platforms, for metabolite and lipid discovery; 3) performs LC/MS method development for custom metabolite assays tailored to individual needs; and 4) provides education and training in the use of the these technologies. The Metabolomics Core has four triple quadrupole mass spectrometers, two high resolution instruments (one for metabolomics and lipidomics, and one for protein quantification), Agilent 1290 Infinity HPLC and 6495B triple quadrupole mass spectrometers for targeted metabolomics and a Thermo Fisher Scientific UHPLC/Orbitrap ID-X mass spectrometer for untargeted metabolomics and lipidomics. ACC members accounted for 26 of 56 investigators (46%) using the Shared Resource during the most recent reporting period (07/01/18-06/30/19). As one example of high impact research dependent upon the Metabolomics Core Shared Resource, Dr. Carl June (Immunobiology) evaluated the attributes of CAR costimulatory domains and demonstrated that CAR-T cells with 4-1BB coreceptors increase respiratory capacity, fatty acid oxidation and mitochondrial biogenesis, in contrast to CAR-T cells with CD28 coreceptors which had metabolomics consistent with enhanced glycolysis in effector memory cells (Kawalekar et al., Immunity, 2016), which has already impacted clinical trial design. The Metabolomics Core is supported by the ACC in partnership with Penn's Cardiovascular Institute and the Institute for Diabetes, Obesity and Metabolism. The mission of the Metabolomics Core is to provide ACC members with a world-class platform providing new discoveries and insight into cellular metabolic mechanisms, which can be integrated with genetics, epigenetics, cell signaling, and other molecular bases of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088764
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Han, Joseph; Lachance, Catherine; Ricketts, M Daniel et al. (2018) The scaffolding protein JADE1 physically links the acetyltransferase subunit HBO1 with its histone H3-H4 substrate. J Biol Chem 293:4498-4509
Waxman, Adam J; Clasen, Suparna; Hwang, Wei-Ting et al. (2018) Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. JAMA Oncol 4:e174519
Gangadhar, Tara C; Savitch, Samantha L; Yee, Stephanie S et al. (2018) Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. Pigment Cell Melanoma Res 31:73-81
Reshef, Ran; Ganetsky, Alex; Acosta, Edward P et al. (2018) Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. Biol Blood Marrow Transplant :
Lang, Fengchao; Sun, Zhiguo; Pei, Yonggang et al. (2018) Shugoshin 1 is dislocated by KSHV-encoded LANA inducing aneuploidy. PLoS Pathog 14:e1007253
Rosenfeld, Aaron M; Meng, Wenzhao; Luning Prak, Eline T et al. (2018) ImmuneDB, a Novel Tool for the Analysis, Storage, and Dissemination of Immune Repertoire Sequencing Data. Front Immunol 9:2107
Kushner, Carolyn J; Hwang, Wei-Ting; Wang, Shiyu et al. (2018) Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer. Breast Cancer Res Treat 170:45-53
Buljan, Vlado A; Graeber, Manuel B; Holsinger, R M Damian et al. (2018) Calcium-axonemal microtubuli interactions underlie mechanism(s) of primary cilia morphological changes. J Biol Phys 44:53-80
Min, Eun Jeong; Safo, Sandra E; Long, Qi (2018) Penalized Co-Inertia Analysis with Applications to -Omics Data. Bioinformatics :
Chang, Changgee; Kundu, Suprateek; Long, Qi (2018) Scalable Bayesian variable selection for structured high-dimensional data. Biometrics :

Showing the most recent 10 out of 1047 publications